Share:

Cushman & Wakefield Awarded QIAGEN Citylabs 2.0 Brief

16/09/2020

QIAGEN, a global leader in Sample to Insight solutions for molecular testing has appointed Cushman & Wakefield to provide Project & Development Services for its £35m new base in Manchester.

The firm will be acting as Project Managers, Cost Consultants, Mechanical and Electrical Consultants and Health and Safety Advisor to deliver the Cat A and B fit out for QIAGEN’s European Hub for Diagnostics Development, part of the Citylabs 2.0 development in Manchester.

QIAGEN has pre-let 92,000 sq ft, including life science laboratories and 40,000 sq ft of support office space, at the scheme which is due for completion in spring 2021. QIAGEN’s relocation from its current base at Manchester Science Park will see them become the anchor industrial partner in the genomics campus.

Citylabs 2.0 is the first phase of a £60m extension of the genomics campus for Manchester Science Partnerships (MSP) in a joint venture with Manchester University NHS Foundation Trust (MFT). It is located within Europe’s largest clinical academic campus and is surrounded by the Manchester Royal Infirmary, Royal Manchester Children’s Hospital, Saint Mary’s Hospital and Manchester Royal Eye Hospital.

Gareth Collins-Jones, Head of Northern Project Management at Cushman & Wakefield, said: “We are delighted to have been commissioned to provide full construction related services to our globally renowned client QIAGEN on this major European hub for Research and Development in life science.

“Our focus is to deliver a highly technical and exceptional workplace on time and within our client’s budget and work with the many outside stakeholders of the development including NHS and Manchester Science Park. We will complete this significant project in spring 2021 and enable a smooth transitional phased move from the current research facility whilst maintaining ongoing research projects.”  

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. It provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2020, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. The company currently has about 270 employees in Manchester and is committed to further growth.

MEDIA CONTACT

Seetle Dool Cushman & Wakefield

RECENT NEWS

Swansea City Centre & Beach
Search for a Strategic Partner to Shape Swansea Begins

Swansea Council has officially launched its search for an experienced and committed partner to help it deliver its vision for a vibrant and distinctive city in which to live, work and spend quality time.

09/09/2020

Modern warehouse
Marchmont buys Virgin's facility in Crawley

Marchmont Investment Management in conjunction with Pictet Alternative Advisors have purchased the freehold interest in Virgin Atlantic’s Training Centre in Crawley for c.£30 million.

24/08/2020

data center
Cushman & Wakefield Identifies Emerging European Data Centre Hotspots

New research from Cushman & Wakefield has identified Berlin, Reykjavik, Oslo, Warsaw, Zurich, Milan, Vienna, Madrid and Prague as emerging hotspots for data centre development in Europe.

18/08/2020

CAN'T FIND WHAT YOU'RE LOOKING FOR?

Get in touch with one of our professionals.